Omics, Bioinformatics and Flow Cytometry Core
Omics, Bioinformatics and Flow Cytometry Core
批准号:
10630580
负责人:
MICHAEL R GARRETT
金额:
$22.41万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-15 至 2028-06-30
关键词:
African American populationApoptosisBioinformaticsBiologicalBiological AssayBiological ProcessCardiorenal syndromeCell CycleCell NucleusCell ProliferationCell SeparationCellsCenters of Research ExcellenceClinicalComplementConsultationsCountryData SetDiseaseEnhancement TechnologyEnsureEquipmentFacultyFaculty WorkshopFlow CytometryFundingGene ExpressionGenerationsGeneticGenomicsGoalsHealthHigh PrevalenceHistorically Black Colleges and UniversitiesImmuneInfrastructureInstitutionInstructionMaintenanceMass Spectrum AnalysisMetabolic DiseasesMethodologyMississippiMolecularMolecular AnalysisMolecular BiologyMorbidity - disease rateNamesNucleic AcidsObesityPhasePhenotypePilot ProjectsPopulationProteomicsQuality ControlResearchResearch PersonnelResearch Project GrantsResourcesScientific Advances and AccomplishmentsScientistServicesSmall RNASortingStudentsSupervisionSystems BiologyTechnical ExpertiseTechniquesTechnologyTraining and EducationUnited StatesWorkXCL1 genecell typecomplex dataepigenomegenome sequencinggenomic dataglucose uptakeimprovedinsightinstrumentinstrumentationmeetingsmortalitymultidisciplinarymultiple omicsnext generation sequencingprogramsrelease of sequestered calcium ion into cytoplasmservice deliverysingle-cell RNA sequencingtraining opportunitytranscriptometranscriptome sequencingtranscriptomicsundergraduate studentwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CORE C – OMICS, BIOINFORMATICS AND FLOW CYTOMETRY CORE
PROJECT SUMMARY/ABSTRACT
The goal of the Cardiorenal and Metabolic Disease Research Center (CMDRC) COBRE is to bring together
a multidisciplinary group of basic, clinical, and population scientists to work synergistically on the theme of
cardiorenal and metabolic diseases. During Phases 1 and 2, the CMDRC - Core C provided COBRE
investigators and external researchers access to technical expertise and equipment to perform a wide variety
of molecular, genetic, and next generation sequencing studies. During Phases 1 and 2, Core C also made
major advances toward ensuring sustainability of its services. During Phase 3, the newly named Core C -
Omics, Bioinformatics and Flow Cytometry will extend its services and offer cutting-edge cellular and
molecular analysis through building on existing infrastructure supported in Phases 1 and 2 (Genomics and
Mass Spectrometry) to offer new cutting-edge omics methodologies as well as offer new capabilities through
recently acquired state-of-the-art cell sorting and flow cytometry equipment. The Omics and Bioinformatics
Sub-Core and Cell Sorting/Flow Cytometry Sub-Core will allow CMDRC investigators comprehensive
molecular or systems biology approaches to their research questions through detailed insight into cell-type
specific function, generation of “omics” datasets, and ultimately integration with detailed phenotype
information to provide greater depth and insight into biological processes associated with obesity, cardiorenal,
and metabolic diseases. Core C has four aims: (1) to provide CMDRC investigators access to technical
expertise and cutting-edge omics services, including next generation sequencing technologies (single cell
RNA sequencing, spatial transcriptomics) and facilitate proteomic technologies by leveraging existing IDeA
funded infrastructure (offer and coordinate proteomics services and through IDeA National Resource for
Quantitative Proteomics program); (2) to provide CMDRC investigators access to cutting-edge cell sorting
and flow cytometry expertise and services; (3) to provide education and training opportunities for students,
trainees, and faculty in omics technologies and flow cytometry; and (4) to provide continuous improvement in
existing assays and services and to enhance technological capabilities through acquisition of new cutting-
edge instrumentation that will assist in sustainability of the Core. Therefore, it is the objective of the CMDRC
- Core C to aid investigators in advancing scientific discovery in obesity, cardiorenal, and metabolic diseases
through application of state-of-the-art cell sorting, flow cytometry, and omics technologies to generate greater
insights into these diseases. Aside from CMDRC investigators, continued funding of the COBRE during Phase
3 will have a significant impact on providing external researchers (at other Mississippi undergraduate
institutions and Historically Black Colleges and Universities (HBCUs)) access to equipment and expertise that
would otherwise not be available in our region of the country.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1 - TBD
-
批准号:10553868
-
项目类别:
-
资助金额:$21.1万
-
财政年份:2023
-
负责人:MICHAEL R GARRETT
-
依托单位:
Molecular Center of Health and Disease
-
批准号:10553864
-
项目类别:
-
资助金额:$228.38万
-
财政年份:2023
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core B-Omics and Gene-Editing
-
批准号:10553866
-
项目类别:
-
资助金额:$48.28万
-
财政年份:2023
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core A- Administration, Education, and Mentoring
-
批准号:10553865
-
项目类别:
-
资助金额:$56.84万
-
财政年份:2023
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetic Targets of Hypertension End Organ Damage
-
批准号:10198017
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2018
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetic Targets of Hypertension End Organ Damage
-
批准号:9920359
-
项目类别:
-
资助金额:$3.35万
-
财政年份:2018
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
-
批准号:10403631
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2013
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
-
批准号:10159921
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2013
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:8477235
-
项目类别:
-
资助金额:$35.23万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:8289584
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:8123186
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:7906923
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:7715407
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetic Analysis of Renal Disease in SHR and Dahl S Rats
-
批准号:6637544
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2001
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
-
批准号:9920748
-
项目类别:
-
资助金额:$36.6万
-
财政年份:--
-
负责人:MICHAEL R GARRETT
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: